Benitec Biopharma Ltd ADR (BNTC NASDAQ) stock market data APIs
$11.9429
-0.14(-1.2%)
as of January 6, 2026
Try our APIs with
free plan!
Benitec Biopharma Ltd ADR Financial Data Overview
Price chart is built with
Anychart
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Prev. Close
11.9429
Open
11.8057
High
11.944
Low
11.1919
52 wk Range
9.7-17.15
Market Cap
406 M
Shares Outstanding
33 862 K
Revenue
7 000
EPS
-0.22
Beta
0.191
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Benitec Biopharma Ltd ADR (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Benitec Biopharma Ltd ADR data using free add-ons & libraries
Get Benitec Biopharma Ltd ADR Fundamental Data
Benitec Biopharma Ltd ADR Fundamental data includes:
- Net Revenue: 7 000
- EBITDA: -45 723 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-17
- EPS/Forecast: -0.356
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Benitec Biopharma Ltd ADR News
New
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares
Key Points New York City-based Suvretta Capital Management sold nearly 1.1 million ARQT shares during the third quarter. The move contributed to a decline in the overall position value by about $35.7...
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares
Key Points New York City-based Suvretta Capital Management sold nearly 1.1 million ARQT shares during the third quarter. The move contributed to a decline in the overall position value by about $35.7...
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears
Key Points New York City-based Suvretta Capital Management increased its MLYS position by 387,641 shares in the third quarter. The overall position value increased by $57.25 million from the previous...
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears
Key Points New York City-based Suvretta Capital Management increased its MLYS position by 387,641 shares in the third quarter. The overall position value increased by $57.25 million from the previou...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
